Dyax and ZymoGenetics Enter Into Library License Agreement for Discovery of Therapeutic Antibodies
Dyax Corp. announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to ZymoGenetics, Inc. for the discovery of therapeutic antibodies. This collaboration with ZymoGenetics is part of Dyax's Licensing and Funded Research Program (LFRP) partnered with Paul Royalty Fund.
Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, clinical milestone payments, and royalties on net sales of products that may result from ZymoGenetics's use of the Dyax libraries. The agreement provides ZymoGenetics a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's antibody phage display technology.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
SYGNIS AG reinforces its proteomics portfolio with two patents granted in Europe and China
Scientists discover novel role for self-recycling process in the brain - Proteins classically associated with autophagy regulate the speed of intracellular transport
Category:Muscarinic_agonists
PregLem announces positivie phase III results from Esmya - PEARL I trial meets primary efficacy and safety endpoints
SynCo Bio Partners B.V. is Now Wacker Biotech B.V.
MDS Pharma Services opens its first U.S. central lab
Institute of Bioengineering and Nanotechnology (IBN) - Singapur, Singapore
Team develops strategy to determine how non-coding variants contribute to disease risk

Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin - "Looking ahead to 2025 and beyond, we are focusing on implementing our One Lonza strategy..."
Amgen Completes Acquisition of Abgenix - Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen
